Project Oncology®
Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer.
Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.
16-30 of 437
A New Era of Hope in Non-Small Cell Lung Cancer Care
Project Oncology®A New Era of Hope in Non-Small Cell Lung Cancer Care
Geoffrey Oxnard, MD
Improving Adherence and Toxicity Monitoring in NSCLC Care
Project Oncology®Improving Adherence and Toxicity Monitoring in NSCLC Care
Raghava Reddy Induru, MD
The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
Project Oncology®The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
Raghava Reddy Induru, MD
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Project Oncology®Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Laura Alder, MD
Key Questions Shaping Antibody-Drug Conjugate Use in NSCLC
Project Oncology®Key Questions Shaping Antibody-Drug Conjugate Use in NSCLC
Laura Alder, MD
Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Project Oncology®Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Laura Alder, MD
- advertisement
The Importance of Multidisciplinary Coordination in NSCLC Care
Project Oncology®The Importance of Multidisciplinary Coordination in NSCLC Care
Laura Alder, MD
Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
Project Oncology®Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
Christine Bestvina, MD
Innovations Shaping the Future of Antibody-Drug Conjugates in NSCLC
Project Oncology®Innovations Shaping the Future of Antibody-Drug Conjugates in NSCLC
Christine Bestvina, MD
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Project Oncology®Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Alexandria May, PharmD, BCPS
Shannon Raber, MS, CPNP, RN
Bridget Archambault, MSN, CPNP
Moving Toward Biomarker-Driven Care in Bladder Cancer
Project Oncology®Moving Toward Biomarker-Driven Care in Bladder Cancer
Benjamin Garmezy, MD
Optimizing Patient Selection for Perioperative Therapy in Bladder Cancer
Project Oncology®Optimizing Patient Selection for Perioperative Therapy in Bladder Cancer
Benjamin Garmezy, MD
- advertisement
What's Next for Urothelial Cancer Treatment?
Project Oncology®What's Next for Urothelial Cancer Treatment?
Benjamin Garmezy, MD
Myeloid Mutations in ALL: Disease Risk and Prognostic Implications
Project Oncology®Myeloid Mutations in ALL: Disease Risk and Prognostic Implications
Caner Saygin, MD
Moving Beyond Chemotherapy in Mantle Cell Lymphoma Care
Project Oncology®Moving Beyond Chemotherapy in Mantle Cell Lymphoma Care
Jonathon Cohen, MD, MS